基因重组人生长激素治疗COPD并发自发性气胸

Application of recombinant human growth hormone for spontaneous pneumothorax complicated with chronic obstructive pulmonary disease

目的:研究基因重组人生长激素(r-hGH)对慢性阻塞性肺疾病(COPD)急性加重期并发自发性气胸的治疗作用。方法:24例COPD急性加重期并发自发性气胸患者随机分成生长激素组和对照组。两组均给予胸腔闭式引流、抗感染、氧疗、营养支持治疗等。生长激素组在上述治疗基础上加用r-hGH,每晚1次皮下注射,连续应用7d。观察各组的胸腔闭式引流时间、疗程及生长激素组治疗前后空腹血糖及胰岛素用量。结果:生长激素组平均胸腔闭式引流时间为(5.1±1.9)d,较对照组的(7.0±2.1)d短(P<0.05);平均疗程为(8.6±2.6)d,较对照组的(11.5±3.2)d短(<0.05)。生长激素组治疗前后空腹血糖及胰岛素用量无显著性差异。结论:r-hGH能够缩短COPD急性加重期并发自发性气胸患者的胸腔闭式引流时间和疗程。

Objective： To investigate the effects of recombinant human growth hormone （r-hGH） in patients with spontaneous pneumothorax complicated with acute exacerbations of chronic obstructive pulmonary disease （COPD）. Methods： 24 patients with spontaneous pneumothorax complicated with acute exacerbations of COPD were randomly divided into r-hGH group and control group. Patients of each group were treated with thoracic close drainage, antibiotic, oxygen therapy and allowance of nutrients. The r-hGH was injected subcutaneously to the patients of r-hGH group every evening for 7 days. The thoracic close drainage days, treatment days in each group, the fasting blood glucose content and insulin dosage before and after treatment in r-hGH group were observed. Results： The average thoracic close drainage days and treatment days in r-hGH group were （5.1±1.9） days and （8.6±2.6） days, which were less than those of control group [（7.0±2.1） days and （11.5±3.2） days respectively] （both P〈0.05）. There was no significant difference in fasting blood glucose content and insulin dosage before and after the treatment in r-hGH group. Conclusion： The thoracic close drainage days and treatment days for spontaneous pneumothorax complicated with acute exacerbations of COPD can be reduced by the use of recombinant human growth hormone.